Sinocare showcases its latest integrated digital health solutions at the European Association for the Study of Diabetes (EASD) meeting in Milan, emphasising AI and interconnected monitoring for diabetes care across home, pharmacy, and hospital settings.
Sinocare is using this week’s European Association for the Study of Diabetes meeting in Milan to present what it describes as a more connected approach to chronic disease management, linking screening, monitoring and follow-up across home, pharmacy and hospital settings.
According to the company’s announcement, the portfolio on display includes devices for blood glucose testing at home, a multi-parameter analyser for community pharmacies and hospital-oriented tools designed to support bedside monitoring and risk screening. Among the products highlighted are the Safe AQ max II blood glucose monitoring system, which the firm says gives a result in five seconds and can sync data by Bluetooth, and the KUG-11 meter, which measures glucose, uric acid and ketones in one device.
Sinocare also said it is targeting pharmacy-based care with the iCARE-1300 portable analyser, which it says can test close to 100 parameters, including blood glucose, lipids, HbA1c and renal function. In hospitals, the company is promoting the AGEscan fluorescence detector for non-invasive screening of advanced glycation end products, a marker linked to long-term blood sugar exposure, alongside the Safe AQ 8000 management system, which it says can connect with hospital information systems and combine readings from glucose meters and continuous glucose monitoring devices.
The Milan appearance follows earlier trade-show presentations in which Sinocare has emphasised digital health, connected devices and artificial intelligence as part of a broader push into integrated chronic disease management. Hospital Medica reported earlier this year that the company had framed its portfolio around AI-driven analytics and ecosystem partnerships at the China International Medical Equipment Fair, while Sinocare’s own materials from another exhibition in Melbourne highlighted its continuous glucose monitoring technology and its use in both diabetes care and companion animals. Those claims show the company is continuing to position itself as a provider of connected monitoring tools rather than a maker of stand-alone devices.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
